Paper3858013
Identification of anthracycline analogues with enhanced cytotoxicity and lack of cross-resistance to adriamycin using a series of mammalian cell lines in vitro.
Hill BT and 3 others. Cancer Chemother Pharmacol, 1985. Cited by 30 papers, by iCite.
Cite this record
ConductScience Library. Identification of anthracycline analogues with enhanced cytotoxicity and lack of cross-resistance to adriamycin using a series of mammalian cell lines in vitro. Papers, record 3858013. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3858013
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Identification of anthracycline analogues with enhanced cytotoxicity and lack of cross-resistance to adriamycin using a series of mammalian cell lines in vitro.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibiotics, Antineoplastic | Major topic |
| Colony-Forming Units Assay | Major topic |
| Doxorubicin | Major topic |
| Tumor Stem Cell Assay | Major topic |
| Animals | |
| Cell Line | |
| Cricetinae | |
| Drug Resistance | |
| Humans | |
| Mesocricetus | |
| Naphthacenes |
Source PubMed
References33
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 6590531 | Phase I trial of aclacinomycin-A. A clinical and pharmacokinetic study. | Invest New Drugs | 1983 | https://conductscience.org/library/papers/6590531 | PubMed |
| 2 | 6987066 | Lethal and kinetic effects of DDMP (2,4-diamino-5-(3',4'-dichlorophenyl)-6-methylpyrimidine). | Eur J Cancer (1965) | 1980 | https://conductscience.org/library/papers/6987066 | PubMed |
| 3 | 423191 | Synthesis and antitumor activity of 4'-O-methyldaunorubicin, 4'-O-methyladriamycin, and their 4'-epi analogues. | J Med Chem | 1979 | https://conductscience.org/library/papers/423191 | PubMed |
| 4 | 6538489 | Phase II study of 9-hydroxy-2N-methylellipticinium acetate. | Eur J Cancer Clin Oncol | 1984 | https://conductscience.org/library/papers/6538489 | PubMed |
| 5 | 7448758 | Cell kill kinetics of several nogalamycin analogs and adriamycin for Chinese hamster ovary, L1210 leukemia, and B16 melanoma cells in culture. | Cancer Res | 1981 | https://conductscience.org/library/papers/7448758 | PubMed |
| 6 | 6590532 | Clinical evaluation of 4'-epi-doxorubicin in advanced solid tumors. | Invest New Drugs | 1983 | https://conductscience.org/library/papers/6590532 | PubMed |
| 7 | 7200828 | Cytotoxic effects and biological activity of 2-aza-8-germanspiro[4,5]-decane-2-propanamine-8,8-diethyl-N,N-dimethyl dichloride (NSC 192965; spirogermanium) in vitro. | Cancer Res | 1982 | https://conductscience.org/library/papers/7200828 | PubMed |
| 9 | 7214352 | Activity of mitoxantrone in a human tumor cloning system. | Cancer Res | 1981 | https://conductscience.org/library/papers/7214352 | PubMed |
| 10 | 287555 | Biochemical parameters of growth inhibition of human leukemia cells by antitumor anthracycline agents. | Cancer Treat Rep | 1979 | https://conductscience.org/library/papers/287555 | PubMed |
| 11 | 6678865 | Phase I clinical trial of a new anthracycline: 4'-o-tetrahydropyranyl adriamycin. | Invest New Drugs | 1983 | https://conductscience.org/library/papers/6678865 | PubMed |
| 12 | 986302 | The value of adriamycin in overcoming resistance to methotrexate in tissue culture. | Eur J Cancer (1965) | 1976 | https://conductscience.org/library/papers/986302 | PubMed |
| 13 | 688281 | Adriamycin therapy for advanced ovarian carcinoma recurrent after chemotherapy. | Cancer Treat Rep | 1978 | https://conductscience.org/library/papers/688281 | PubMed |
| 14 | 709555 | In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia. | Cancer Treat Rep | 1978 | https://conductscience.org/library/papers/709555 | PubMed |
| 15 | 6936969 | Antileukemic activity of 4-demethoxydaunorubicin in mice. | Tumori | 1980 | https://conductscience.org/library/papers/6936969 | PubMed |
| 16 | 144604 | Flow microfluorometric estimation of G1 and G2 chalone inhibition of the JB-1 tumour cell cycle in vitro. | Exp Cell Res | 1977 | https://conductscience.org/library/papers/144604 | PubMed |
| 17 | 7105379 | Antitumor activity of mitoxantrone against murine experimental tumors: comparative analysis against various antitumor antibiotics. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/7105379 | PubMed |
| 18 | 565251 | Tumor and lymphoid cell lines from a patient with carcinoma of the colon for a cytotoxicity model. | Cancer Res | 1978 | https://conductscience.org/library/papers/565251 | PubMed |
| 19 | 7060020 | 4'-O-tetrahydropyranyladriamycin as a potential new antitumor agent. | Cancer Res | 1982 | https://conductscience.org/library/papers/7060020 | PubMed |
| 20 | 7105380 | Establishment of Vincristine-resistant and vindesine-resistant lines of murine lymphoblasts in vitro and characterisation of their patterns of cross-resistance and drug sensitivities. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/7105380 | PubMed |
| 21 | 6946877 | Evaluation of new anthracycline analogs with the human tumor stem cell assay. | Cancer Chemother Pharmacol | 1981 | https://conductscience.org/library/papers/6946877 | PubMed |
Cited by15
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 30 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 8422694 | Decreased resistance to N,N-dimethylated anthracyclines in multidrug-resistant Friend erythroleukemia cells. | Cancer Chemother Pharmacol | 1993 | https://conductscience.org/library/papers/8422694 | PubMed |
| 8261573 | Effect of pH and moderate hyperthermia on doxorubicin, epirubicin and aclacinomycin A cytotoxicity for Chinese hamster ovary cells. | Cancer Chemother Pharmacol | 1993 | https://conductscience.org/library/papers/8261573 | PubMed |
| 8099807 | Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines. | Br J Cancer | 1993 | https://conductscience.org/library/papers/8099807 | PubMed |
| 7779709 | In vitro anthracycline cross-resistance pattern in childhood acute lymphoblastic leukaemia. | Br J Cancer | 1995 | https://conductscience.org/library/papers/7779709 | PubMed |
| 3730255 | Characterization of a doxorubicin-resistant murine melanoma line: studies on cross-resistance and its circumvention. | Br J Cancer | 1986 | https://conductscience.org/library/papers/3730255 | PubMed |
| 3718817 | 9-alkyl anthracyclines. Absence of cross-resistance to adriamycin in human and murine cell cultures. | Br J Cancer | 1986 | https://conductscience.org/library/papers/3718817 | PubMed |
| 3621454 | Selective interactions of verapamil with anthraquinones in adriamycin-sensitive and -resistant murine and human tumour cell lines in vitro. | Cancer Chemother Pharmacol | 1987 | https://conductscience.org/library/papers/3621454 | PubMed |
| 3472676 | Relative cardiotoxicity and cytotoxicity of anthraquinonyl glucosaminosides. | Cancer Chemother Pharmacol | 1987 | https://conductscience.org/library/papers/3472676 | PubMed |
| 3459509 | The in vitro effects and cross-resistance patterns of some novel anthracyclines. | Br J Cancer | 1986 | https://conductscience.org/library/papers/3459509 | PubMed |
| 3011054 | Derivation and preliminary characterisation of adriamycin resistant lines of human lung cancer cells. | Br J Cancer | 1986 | https://conductscience.org/library/papers/3011054 | PubMed |
| 2574988 | In vitro evaluation of the potential of aclarubicin in the treatment of small cell carcinoma of the lung (SCCL). | Br J Cancer | 1989 | https://conductscience.org/library/papers/2574988 | PubMed |
| 2547527 | Identification of anthracyclines and related agents that retain preferential activity over adriamycin in multidrug-resistant cell lines, and further resistance modification by verapamil and cyclosporin A. | Cancer Chemother Pharmacol | 1989 | https://conductscience.org/library/papers/2547527 | PubMed |
| 2337680 | Toxicity of novel anthracycline derivatives towards normal myeloid bone marrow progenitor cells (CFU-GM) is not increased by verapamil. | Blut | 1990 | https://conductscience.org/library/papers/2337680 | PubMed |
| 2311171 | DNA damage and cytotoxicity of mitoxantrone and doxorubicin in doxorubicin-sensitive and -resistant human colon carcinoma cells. | Cancer Chemother Pharmacol | 1990 | https://conductscience.org/library/papers/2311171 | PubMed |
| 1973363 | Patterns of cross-resistance in a multidrug-resistant small-cell lung carcinoma cell line. | Cancer Chemother Pharmacol | 1990 | https://conductscience.org/library/papers/1973363 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/3858013
GET https://conductscience.org/api/papers/v1/3858013/references?page=2